John Mendelsohn

Q: What Schools Are Affiliated With John Mendelsohn

John Mendelsohn is affiliated with the following schools: Harvard University, Rice University, MD Anderson Cancer Center, University of California, San Diego, Cornell University

John Mendelsohn 's AcademicInfluence.com Rankings

John Mendelsohn

Philosophy

#3992

World Rank

#6347

Historical Rank

#1214

USA Rank

Logic

#1948

World Rank

#2826

Historical Rank

#516

USA Rank

philosophy Degrees

Download Badge

Philosophy

Why Is John Mendelsohn Influential?

(Suggest an Edit or Addition)

According to Wikipedia, John Mendelsohn was a president of the University of Texas MD Anderson Cancer Center in Houston. He was an internationally recognized leader in cancer research. Mendelsohn served as MD Anderson president from 1996 to 2011. When Ronald DePinho became president, he stepped down September 1, 2011. Mendelsohn remained on the faculty as co-director of the new Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy. Also, he was a senior fellow in health and technology at the Baker Institute.

(See a Problem?)

John Mendelsohn 's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. (1996) (1402)
The EGF receptor family as targets for cancer therapy (2000) (1372)
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. (2003) (1278)
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. (1998) (1085)
Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. (1995) (838)
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. (2000) (759)
Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. (1983) (756)
Epidermal growth factor receptor targeting in cancer. (2006) (706)
Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. (1984) (556)
In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. (2000) (531)
Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. (1983) (471)
Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. (1993) (458)
Targeting the epidermal growth factor receptor for cancer therapy. (2002) (451)
Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. (1993) (444)
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells (2003) (444)
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. (2000) (395)
Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. (1995) (394)
The Molecular Basis of Cancer (1985) (370)
Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. (1984) (364)
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. (2015) (342)
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. (1999) (339)
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. (2015) (334)
Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. (1997) (332)
Heregulin Regulates Cytoskeletal Reorganization and Cell Migration through the p21-activated Kinase-1 via Phosphatidylinositol-3 Kinase* (1998) (313)
Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. (2001) (311)
Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. (1996) (310)
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. (1999) (309)
Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. (1994) (300)
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial (2019) (294)
Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. (2001) (292)
Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. (1993) (272)
Formation of p27-CDK complexes during the human mitotic cell cycle. (1996) (262)
The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. (1996) (261)
Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. (1996) (254)
Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. (1986) (249)
Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells. (1984) (242)
Regulation of Cyclooxygenase-2 pathway by HER2 receptor (1999) (242)
Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. (2016) (239)
The epidermal growth factor receptor as a target for cancer therapy. (2001) (238)
Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. (1995) (233)
Physical Interaction between Epidermal Growth Factor Receptor and DNA-dependent Protein Kinase in Mammalian Cells* (1998) (233)
Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. (1986) (216)
PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. (1997) (206)
Blockade of receptors for growth factors: an anticancer therapy--the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture. (2000) (198)
Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha. (1991) (192)
The rapid induction by phytohemagglutinin of increased alpha-aminoisobutyric acid uptake by lymphocytes. (1971) (188)
Epidermal growth factor receptor family and chemosensitization. (1997) (186)
A decision support framework for genomically informed investigational cancer therapy. (2015) (168)
Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. (2007) (156)
A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program (2010) (153)
Augmentation of a humanized Anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225 (1999) (151)
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. (1996) (150)
Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. (2015) (145)
Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells. (1989) (145)
Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c- jun N-terminal kinase activity (2000) (143)
Effects of epidermal growth factor receptor concentration on tumorigenicity of A431 cells in nude mice. (1986) (142)
The role of monocytes in human lymphocyte activation by mitogens. (1979) (142)
Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. (1995) (142)
Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. (2010) (140)
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
Nuclear targeting of Bax during apoptosis in human colorectal cancer cells (1998) (138)
Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. (2000) (136)
Expression of the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Pathway in Normal Human Breast Epithelial Cells (1990) (135)
Personalizing oncology: perspectives and prospects. (2013) (135)
Adenosine metabolism in phytohemagglutinin-stimulated human lymphocytes. (1976) (135)
Inhibition of human natural cytotoxicity by macromolecular antiproteases. (1981) (131)
Therapeutic application of anti‐growth factor receptor antibodies (1998) (130)
Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. (2016) (129)
Prolonged induction of p21Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition (1995) (129)
Ligand-induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly. (1991) (129)
Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma (1993) (126)
Growth Factors Regulate Heterogeneous Nuclear Ribonucleoprotein K Expression and Function* (2001) (125)
Infusional 5‐fluorouracil and x‐ray therapy for non‐resectable esophageal cancer (1980) (124)
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. (2017) (119)
Beyond BRAFV600: clinical mutation panel testing by next-generation sequencing in advanced melanoma (2014) (118)
Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells (1991) (117)
Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody. (1989) (117)
The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. (1990) (115)
The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression (2005) (115)
9-Cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein. (1994) (115)
Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. (1986) (114)
ALK: a tyrosine kinase target for cancer therapy (2017) (113)
Epidermal growth factor-induced growth inhibition requires Stat1 activation. (1998) (113)
Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha. (1992) (111)
Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. (1997) (111)
Building a personalized medicine infrastructure at a major cancer center. (2013) (107)
Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody (2001) (107)
Vascular Endothelial Growth Factor Up-regulation via p21-activated Kinase-1 Signaling Regulates Heregulin-β1-mediated Angiogenesis* (2000) (105)
Ceramide stimulates epidermal growth factor receptor phosphorylation in A431 human epidermoid carcinoma cells. Evidence that ceramide may mediate sphingosine action. (1991) (104)
The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. (1996) (104)
EGF receptor and p185erbB‐2‐specific single‐chain antibody toxins differ in their cell‐killing activity on tumor cells expressing both receptor proteins (1995) (101)
Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. (1987) (100)
Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. (1996) (100)
Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. (1999) (98)
Inhibition of human lymphocyte stimulation by steroid hormones: cytokinetic mechanisms. (1977) (97)
Clinical actionability enhanced through deep targeted sequencing of solid tumors. (2015) (96)
Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies. (1986) (90)
The epidermal growth factor receptor as a target for therapy in breast carcinoma (2004) (90)
Role of transferrin, Fe, and transferrin receptors in myeloid leukemia cell growth. Studies with an antitransferrin receptor monoclonal antibody. (1985) (90)
Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines (2001) (89)
Epidermal Growth Factor Receptor Monoclonal Antibody Inhibits Constitutive Receptor Phosphorylation, Reduces Autonomous Growth, and Sensitizes Androgen-independent Prostatic Carcinoma Cells to Tumor Necrosis Factor α (1992) (89)
Receptor blockade with monoclomal antibodies as anti-cancer therapy (1994) (88)
Blockage of EGF receptor signal transduction causes reversible arrest of normal and immortal human mammary epithelial cells with synchronous reentry into the cell cycle. (1993) (87)
Consumption of EGF by A431 cells: evidence for receptor recycling (1993) (84)
Autocrine Regulation of Membrane Transforming Growth Factor- Cleavage (*) (1996) (79)
Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. (1998) (78)
Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. (1981) (77)
Serine phosphorylation of paxillin by heregulin-β1: role of p38 mitogen activated protein kinase (1999) (77)
Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. (1997) (74)
Basic fibroblast growth factor causes growth arrest in MCF-7 human breast cancer cells while inducing both mitogenic and inhibitory G1 events. (1997) (72)
Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. (2015) (72)
Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. (1999) (68)
Inhibition of human lymphocyte proliferation by monoclonal antibody to transferrin receptor. (1983) (68)
Autonomous proliferation of colon cancer cells that coexpress transforming growth factor alpha and its receptor. Variable effects of receptor-blocking antibody. (1992) (68)
Circulating tumor cells in breast cancer: Advanced tools for “tailored” therapy? (2006) (64)
Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic (2003) (64)
Requirement of hypoxia-inducible factor-1α down-regulation in mediating the antitumor activity of the anti–epidermal growth factor receptor monoclonal antibody cetuximab (2008) (63)
Enhanced effects of prostaglandin E1 and dibutyryl cyclic AMP upon human lymphocytes in the presence of cortisol. (1973) (63)
EGF induces cell cycle arrest of A431 human epidermoid carcinoma cells (1986) (62)
Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides. (1996) (60)
Differential modulation of paclitaxel-mediated apoptosis by p21Waf1 and p27Kip1 (2000) (60)
Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain. (1989) (59)
Separation of isolated Chinese hamster metaphase chromosomes into three size-groups. (1968) (56)
From combinatorial peptide selection to drug prototype (II): Targeting the epidermal growth factor receptor pathway (2010) (55)
Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. (2014) (53)
Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-beta1-mediated angiogenesis. (2000) (53)
Growth factor receptors as targets for antitumor therapy with monoclonal antibodies. (1988) (52)
Receptor blockade with monoclonal antibodies as anti-cancer therapy. (1994) (52)
The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. (2015) (51)
Ribonucleotides in closed circular mitochondrial DNA from HeLa cells. (1973) (50)
RNA in nascent DNA from cultured human lymphocytes. (1973) (49)
The carbohydrate specificities of the monoclonal antibodies 29.1, 445 and 3C1B12 to the epidermal growth factor receptor of A431 cells (1985) (49)
Modulation of tyrosine, serine, and threonine phosphorylation and intracellular processing of the epidermal growth factor receptor by antireceptor monoclonal antibody (1990) (49)
Mitogenic action of tumor necrosis factor in human fibroblasts: Interaction with epidermal growth factor and platelet‐derived growth factor (1988) (47)
Isolation and characterization of human metaphase chromosomes. (1966) (47)
Antitumor activity of L-canavanine against L1210 murine leukemia. (1980) (47)
Constitutive overexpression of cyclin D1 in human breast epithelial cells does not prevent G1 arrest induced by deprivation of epidermal growth factor (1999) (47)
Precision Oncology Decision Support: Current Approaches and Strategies for the Future (2018) (46)
Clinical next generation sequencing to identify actionable aberrations in a phase I program (2014) (45)
Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein. (1996) (45)
Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. (2018) (41)
Regulation of epidermal growth factor receptor in NIH3T3/HER14 cells by antireceptor monoclonal antibodies. (1993) (41)
Effects of monoclonal antibodies that block transferrin receptor function on the in vivo growth of a syngeneic murine leukemia. (1987) (41)
Drug-induced agranulocytosis: in vitro evidence for immune suppression of granulopoiesis and a cross-reacting lymphocyte antibody. (1979) (40)
Toxicity of ligand and antibody‐directed ricin A‐chain conjugates recognizing the epidermal growth factor receptor (1987) (39)
Autonomous proliferation of colon cancer cells that coexpress transforming growth factor α and its receptor (1992) (39)
The circulating "atypical" lymphocyte. (1978) (39)
DNA synthesis and proliferation of human lymphocytes in vitro. I. Cell kinetics of response to phytohemagglutinin. (1978) (38)
Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. (1998) (38)
Regulation of TGF‐α expression in human keratinocytes: PKC‐dependent and ‐independent pathways (1992) (37)
Effect of transforming growth factor-beta 1 on proliferation and induction of hemoglobin accumulation in K-562 cells. (1989) (36)
Functional consequence of the MET-T1010I polymorphism in breast cancer (2014) (32)
"Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource. (2017) (32)
Expression of the transforming growth factor-alpha/epidermal growth factor receptor pathway in normal human breast epithelial cells. (1990) (31)
Effects of antiepidermal growth factor receptor antibody 528 on the proliferation and differentiation of head and neck cancer. (1994) (31)
Bioinformatics and systems biology (2012) (31)
Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer. (2009) (30)
Insulin‐like growth factors modulate the growth inhibitory effects of retinoic acid on MCF‐7 breast cancer cells (1995) (30)
Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells. (1998) (30)
Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. (2015) (30)
Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents (1990) (28)
An examination of the role of vitamin E in glucose-6-phosphate dehydrogenase deficiency. (1979) (28)
Adenylate cyclase in thymus-derived and bone marrow-derived lymphocytes from normal donors and patients with chronic lymphocytic leukemia. (1979) (27)
A National Cancer Clinical Trials Network: Recommendations From the Institute of Medicine (2011) (27)
Control of transcription of RNA rich in polyadenylic acid in human lymphocytes. (1972) (26)
Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cells. (2000) (26)
Regulation of Elongation Factor-1α Expression by Growth Factors and Anti-receptor Blocking Antibodies* (2001) (26)
Active tumor cell resistance to human natural killer lymphocyte attack. (1981) (26)
Clinical Use of Precision Oncology Decision Support. (2017) (25)
Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells. (1999) (25)
Turning the Tide Against Cancer Through Sustained Medical Innovation: The Pathway to Progress (2014) (24)
Altered epidermal growth factor signal transduction in activated Ha-ras-transformed human keratinocytes. (1993) (24)
EGF receptors as a target for cancer therapy. (2004) (23)
Tumor receptor imaging: proceedings of the National Cancer Institute workshop, review of current work, and prospective for further investigations. (1995) (23)
Anti-epidermal growth factor receptor monoclonal antibodies may inhibit A431 tumor cell proliferation by blocking an autocrine pathway. (1987) (23)
A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer (2015) (22)
Abnormal modulation of granulocyte/macrophage progenitor proliferation by prostaglandin E in chronic myeloproliferative disorders. (1980) (22)
Role of 2′-5′-Oligoadenylate Synthetase in γ-Interferon-mediated Growth Inhibition of A431 Cells (1989) (22)
Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells. (1993) (22)
Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach. (1996) (22)
Effects of epidermal growth factor on transferrin receptor phosphorylation and surface expression in malignant epithelial cells (1987) (22)
Cooperative antiproliferative effects of 8-chloro-cyclic AMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells. (1995) (22)
Extensive disease small cell carcinoma of the lung. Trial of non‐cross resistant chemotherapy and consolidation radiotherapy (1982) (21)
Anti-EGF receptor monoclonal antibodies: biological studies and potential clinical applications. (1989) (21)
T-cell growth factor-mediated proliferation of lymphocytes from a T-chronic lymphocytic leukaemia patient lacking mitogen and alloantigen responsiveness. (1981) (20)
Growth regulation of A431 cells. Modulation of expression of transforming growth factor-alpha mRNA and 2',5'-oligoadenylate synthetase activity. (1990) (20)
CCR 20th Anniversary Commentary: A Chimeric Antibody, C225, Inhibits EGFR Activation and Tumor Growth (2015) (20)
Jeremiah Metzger Lecture. Targeted cancer therapy. (2000) (20)
Ethanol activation of human natural cytotoxicity. (1983) (20)
Effect of unsaturated fatty acids on human lymphocytes: disparate influences of oleic and linolenic acids on natural cytotoxicity. (1981) (20)
Regulation of TGF-alpha expression in human keratinocytes: PKC-dependent and -independent pathways. (1992) (19)
Involvement of p21Waf1 in mediating inhibition of paclitaxel-induced apoptosis by epidermal growth factor in MDA-MB-468 human breast cancer cells. (2000) (19)
WIN Consortium—challenges and advances (2011) (19)
Clinical outcomes based on multigene profiling in metastatic breast cancer patients (2016) (19)
The Willet F. Whitmore, Jr., Lectureship: blockade of epidermal growth factor receptors as anticancer therapy. (2001) (19)
Characterization of normal peripheral blood lymphocyte colony-forming cells: cell cycle status, surface markers, and cellular growth requirements. (1983) (19)
Kinetics of cell death and disintegration in human lymphocyte cultures. (1977) (19)
The role of growth factor signaling in malignancy. (2003) (18)
Type I Receptor Tyrosine Kinases as Targets for Therapy in Breast Cancer (2004) (18)
Thymidine as a chemotherapeutic agent: pharmacologic, cytokinetic, and biochemical studies in a patient with T-cell acute lymphocytic leukemia. (1980) (17)
Crosstalk between epidermal growth factor receptor and P-glycoprotein in actinomycin D-resistant Chinese hamster lung cells. (1993) (17)
Thymidine as a chemotherapeutic agent: sensitivity of normal human marrow, peripheral blood T cells, and acute nonlymphocytic leukemia. (1980) (17)
Requirement for monocytes in the spontaneous cytotoxic effects of human lymphocytes against non-lymphoid target cells (1980) (17)
Variations in the amount of ribonucleoprotein particles in Escherichia coli (1959) (16)
The role of target cells, monocytes, and Fc receptor-bearing lymphocytes in human spontaneous cell-mediated cytotoxicity and antibody-dependent cellular cytotoxicity. (1980) (16)
The Molecular Basis of Cancer: Fourth Edition (2014) (15)
Transforming growth factor beta modulates phosphorylation of the epidermal growth factor receptor and proliferation of A431 cells. (1992) (15)
Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha. (1992) (15)
A direct radioimmunoassay for human epidermal growth factor receptor using 32P-autophosphorylated receptor. (1985) (13)
Spontaneous lymphocyte proliferation and depressed cellular immunity in Hodgkin's disease. (1978) (13)
Polypeptide growth factors in the regulation of human tumor cell proliferation (1991) (13)
COMMITTEE ON CANCER CLINICAL TRIALS AND THE NCI COOPERATIVE GROUP PROGRAM (2010) (12)
Ligand induced internalization of epidermal growth factor receptors by A431 cells decreases at high cell densities in culture. (1991) (12)
Colony-forming assay for circulating chronic lymphocytic leukemia cells. (1982) (12)
Endocytosis and exocytosis of phytohemagglutinin (PHA) cell surface receptors of human lymphocytes during blast transformation. (1977) (12)
A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory (2017) (12)
DNA synthesis and proliferation of human lymphocytes in vitro. II. Characterization of the DNA newly synthesized after phytohemagglutinin stimulation. (1978) (11)
Phase I trials of thymosin fraction 5 and thymosin α1 (1982) (11)
Physician interpretation of genomic test results and treatment selection (2018) (11)
Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. (2019) (10)
Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. (1992) (10)
Modulation of normal and abnormal myeloid progenitor proliferation by cyclic nucleotides and PGE1. (1980) (10)
Role of transforming growth factor-α-related peptides in the autocrine/paracrine control of experimental breast cancer growthin vitro by estradiol, prolactin, and progesterone (1990) (10)
In vitro sensitivity to steroid hormones and cytotoxic agents of normal and malignant lymphocyte colony-forming cells. (1983) (9)
Personalized cancer medicine – A strategy to counteract an increasing cancer challenge (2012) (8)
A National Cancer Clinical Trials System for Targeted Therapies (2011) (8)
Non-cross-resistant chemotherapy and consolidation radiotherapy for small cell carcinoma of the lung. (1982) (8)
Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel (2016) (8)
The impact of tumor heterogeneity on patient treatment decisions. (2013) (8)
Monoclonal antibodies against the receptor for epidermal growth factor as potential anticancer agents (1987) (7)
WINTHER: An international WIN Consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies. (2018) (7)
Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer (2018) (7)
Impact of precision medicine in refractory malignancies: A meta-analysis of 13,203 patients in phase I clinical trials. (2016) (7)
Antiangiogenic and antitumor activity of anti-EGFR C225 monoclonal antibody in combination with Vascular Endothelial Growth Factor antisense oligonucleotide in human GEO colon cancer cells. (2000) (7)
Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program. (2015) (7)
The requirement for monocytes in spontaneous cytotoxicity by lymphocytes from healthy donors and melanoma patients (1980) (7)
Use of an antibody to target geldanamycin. (2000) (6)
Transfer of specific immunity with RNA. (1978) (6)
3 – Studies of Isolated Mammalian Metaphase Chromosomes (1974) (6)
QUANTIFICATION OF ENTRY INTO AND EXIT FROM THE CELL CYCLE IN HUMAN LYMPHOCYTE CULTURES (1978) (6)
Clinical outcomes based on multigene profiling in metastatic breast cancer patients. (2015) (6)
KINETICS OF DNA SYNTHESIS AND CELL PROLIFERATION IN LYMPHOCYTE ACTIVATION: WORKSHOP REVIEW (1977) (6)
Monoclonal Antibodies Directed towards Growth-Related Receptors on Human Tumors (1985) (5)
On the mechanism for formation of RNA . DNA complexes from lymphocytes. (1975) (5)
Nucleoside requirements for the protection of human marrow from methotrexate (MTX) (1979) (5)
Innovative clinical trials for development of personalized cancer medicine (2015) (4)
Chapter 12 Isolation and Fractionation of Metaphase Chromosomes (1969) (4)
Expression of Epidermal Growth Factor Receptor and Human Papillomavirus E 6 / E 7 Proteins in Cervical Carcinoma Cells (1997) (4)
Epidermal Growth Factor Receptor-targeted Therapy with C 225 and Cisplatin in Patients with Head and Neck Cancer 1 (2001) (4)
Induction of complete remission in T-cell acute lymphoblastic leukemia with deoxycoformycin (dcf) and 9-beta-D-arabinofuranosyladenine (ara-A). (1986) (4)
Modulation of cytosine arabinoside triphosphate (ara-CTP) and trinucleotide pools in a human acute leukemia cell line (HL-60) by thymidine (dThd) and hydroxyurea (HU) (1981) (4)
Reduced expression of c-erbB2 gene product in human mammary carcinoma SK-BR-3 cells treated with interferon-gamma and tumor necrosis factor-alpha. (1994) (4)
SPONTANEOUS LYMPHOCYTE PROLIFERATION IN HODGKIN'S DISEASE (1977) (3)
Hypercalcemia and tamoxifen readministered. (1978) (3)
Combined 5-fluorouracil (5-FU) and X-ray therapy in esophageal and other gastro-intestinal (GI) cancers (1978) (3)
Cooperative inhibition of human renal cancer cell growth by treatment with anti-epidermal growth factor receptor monoclonal antibody and a mixed backbone antisense oligonucleotide targeting type I protein kinase A (1998) (3)
EGF receptor blockade as anticancer therapy (1998) (3)
Role of 2'-5'-oligoadenylate synthetase in gamma-interferon-mediated growth inhibition of A431 cells. (1989) (3)
Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance to the anti-EGFR monoclonal antibody cetuximab (2007) (3)
The Molecular basis of cancer 4th edition, 2015 (2016) (3)
The 2010 Institute of Medicine consensus statement "A national clinical trials network for the 21st century": progress and challenges. (2014) (3)
Adenosine and guanosine metabolism during phytohemagglutinin induced transformation of human lymphocytes. (1977) (3)
Precision Medicine Clinical Trials: Successes and Disappointments, Challenges and Opportunities – Lessons Learnt (2018) (3)
Active Disclosure of Secondary Germline Findings to Deceased Research Participants' Personal Representatives: Process and Outcomes. (2017) (3)
Erratum: Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-Analysis of Clinical Trials Leading to FDA Approval (Journal of the National Cancer Institute (2015) 107:11 (djv253) DOI:10.1093/jnci/djv253) (2016) (3)
DNA synthesis and proliferation of human lymphocytes in vitro: III. Fate of cycling cells in aging cultures of phytohemagglutinin stimulated human lymphocytes (1981) (3)
From Bench to Bedside with Targeted Therapies (2008) (3)
Curbing tobacco's toll starts with the professionals: World No Tobacco Day (2005) (3)
Chapter 43 – From Bench to Bedside with Targeted Therapies (2008) (2)
Anti-EGF receptor monoclonal antibody 528 inhibits proliferation of a subset of human tumor cells in culture and in xenografts (1985) (2)
Moving Discovery into Clinical Practice (2004) (2)
Comprar The Molecular Basis Of Cancer (Online And Print) 4th Ed. | C. Thompson | 9781455740666 | Saunders (2014) (2)
Purification of human interleukin 2 to apparent homogeneity and partial characterization of its receptor. (1984) (2)
Expression of epidermal growth factor receptor and transforming growth factor alpha in human myogenic sarcomas (1992) (2)
Nascent DNA from phytohemagglutinin-stimulated human lymphocytes. (1975) (2)
Poly(A): Possible Role in Translation of Poly(A)-Rich RNA 1 (1973) (2)
Growth factors in human cancer. (1990) (2)
IS THERE GENE AMPLIFICATION OR OTHER NONDUPLICATIVE DNA SYNTHESIS IN HUMAN LYMPHOCYTE ACTIVATION (1977) (2)
An emerging role for prostaglandin E1 in regulation of granulopoiesis. (1981) (1)
Commentary on "Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts" (A Follow Up). (2016) (1)
Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors. (2017) (1)
Merging medicine with science: the birth of a targeted therapy in cancer. (2004) (1)
OMICS AND PROGNSTIC MARKERS (2013) (1)
Anti-EGF receptor monoclonal antibodies as potential anti-cancer therapy (1994) (1)
Hodgkin's disease and anergy (1979) (1)
Physician and Patient Participation in Cancer Clinical Trials (2010) (1)
Growth factors in lung cancer. Current status and implications for therapy (1997) (1)
1 Feasibility of large-scale genomic testing to facilitate enrollment on genomically-matched clinical trials (2014) (1)
Effects of Antiepidermal Growth Factor Receptor Antibody 528 on the Proliferation and Differentiation of Head and Neck Cancer (1994) (1)
Prevalence of incidental germline pathogenic (PV) and likely pathogenic (LPV) variants in hereditary cancer-related genes identified in matched tumor/normal sequencing of advanced solid tumors. (2017) (1)
Characterization and drug treatment of human lymphocytes in a colony assay (1982) (1)
Culture of normal and leukemic human lymphocyte colonies (1981) (1)
Development of a Targeted Treatment for Cancer (2008) (1)
Systematic review of a personalized strategy in cancer clinical trials leading to FDA approval. (2014) (1)
Comprar The Molecular Basis of Cancer | John Mendelsohn | 9781416037033 | Saunders (2008) (1)
Targeting the EGF receptor: experience and lessons (2006) (1)
EGF Receptor Inhibition by Antibody as Anticancer Therapy (1997) (1)
Transforming Growth Factor fi Modulates Phosphorylation of the Epidermal Growth Factor Receptor and Proliferation of A 431 Cells ’ (2005) (1)
Monoclonal antibodies to the epidermal growth factor receptor selectively inhibit the growth of human tumor cells (1985) (1)
Modulation of epidermal growth factor receptor egfr tyrosine kinase activity independent of ligand affinity state (1987) (1)
Abstract PR05: Investigating the importance of low allele frequency mutations for cancer patient management (2015) (0)
EVIDENCE FOR AND AGAINST UNUSUAL SPECIES OF DNA IN LYMPHOCYTE ACTIVATION (1979) (0)
Effects of unsaturated fatty acids and ethanol on human lymphocyte natural cytotoxicity (NK) (1981) (0)
A direct radioimmune assay for human EGF receptor (1985) (0)
31 Rationale for combining EGF receptor blockade with radiation therapy for patients with advanced squamous cell carcinoma of the head and neck (1999) (0)
Regulation of p21-WAF1/CIP1 transcription by epidermal growth factor in human squamous carcinoma cell line A431 (1997) (0)
Customized Cancer Treatment: A Systems Biology Approach to Drug Selection (2011) (0)
INDUCTION OF COMPLETE REMISSION IN T-ALL BY DEOXYCO FARMYCIN (dcf) AND ARA-A: 236 (1985) (0)
Abstract 392: Combined targeting of MET and PI3K improves efficacy in breast cancer models with concurrent MET/PI3K aberrations (2016) (0)
EDITORIALS Use of an Antibody to Target Geldanamycin (2000) (0)
Status o f E pidermal G rowth F actor R eceptor A ntagonists i n the B iology a nd T reatment o f C ancer (2003) (0)
Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation ( phosphotyrosine / Percoll gradient / epidermoid carcinoma cell ) (2003) (0)
Abstract 4276: T200: a high depth targeted exome sequencing platform to identify actionable alterations in FFPE solid tumor samples (2014) (0)
488 Development of a publicly accessible knowledgebase to facilitate decision support for clinical cancer genomics reporting (2014) (0)
Effects of Epidermal Growth Factor Receptor Concentration on Tumorigenicity of A431 Cells in Nude Mice1 (2006) (0)
Regulation of TCF-cx Expression in Human Keratinocytes : PKC-Dependent and-Independent Pathways (2004) (0)
Advances in Brief Involvement of B Lymphocytes in the Growth Inhibition of Human Pulmonary Melanoma Metastases in Athymic flu / flu Mice by an Antibody-Lymphotoxin Fusion Protein 1 (2006) (0)
16 Personalised Cancer Treatment (2012) (0)
Growth Regulation of A431 Cells (2001) (0)
SIGNAL TRANSDUCTION IN CANCER (2005) (0)
Growth factors, hormones, cell growth, surgery, subspecialty investigation: A message from the editor-in-chief (2003) (0)
Therapeutic Interventional Mapping System (TIMS): A novel strategy for the selection of tri-targeted therapy combinations for non-small cell lung cancer (NSCLC). (2015) (0)
Shaking up cancer clinical trials: an interview with John Mendelsohn, M.D., by Joanne Nicholas. (2010) (0)
Activation of HER2 pathway induces expression of cyclooxygenase-2, release of prostaglandin E2, and mitogenesis in human colorectal cancer cells (1998) (0)
Anti-epidermal growth factor (EGF) receptor (R) monoclonal antibodies (mAbs) as potential anti-cancer agents (1990) (0)
Mendelsohn : The EGF receptor as a target for cancer therapy and forms of thyroid (1994) (0)
638 Acquired resistance to EGF receptor-targeted cancer therapy (2004) (0)
Advances in Brief Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 225 UpRegulates p 27 KIP 1 and Induces G ! Arrest in Prostatic Cancer Cell Line DU 1451 (2006) (0)
The Science of Developing Cancer Therapy (2010) (0)
Previous and Ongoing Analyses Undertaken by NCI (2010) (0)
Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory (2019) (0)
Prolonged Induction of p21CiplmAFI/CDK2/PCNA Complex by Epidermal Growth Factor Receptor Activation Mediates Ligand-induced A431 Cell Growth Inhibition (2002) (0)
Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies 1 (2006) (0)
Reply to M.P. Decatris et al. (2016) (0)
Detection of epidermal growth factor receptor (EGFr) on cultured human cell using monoclonal antibodies (mAbs): EGFr is a differentiation antigen (Ag) of cultured melanoma (1985) (0)
New feature: "The Cooperative Group Bulletin Board" (2001) (0)
Clinical utilization of precision oncology decision support for genomically-informed cancer therapy. (2016) (0)
JEREMIAH TARGETED CANCER THERAPY (2007) (0)
Expression of Epidermal Growth Factor Receptor in Human Cultured Cells and Tissues : Relationship to Cell Lineage and Stage of Differentiation 1 (2006) (0)
Development of a public knowledgebase to facilitate decision support for clinical cancer genomics reporting and clinical trial enrollment. (2015) (0)
28 Synergistic antiproliferative effects of ionizing radiations with anti-epidermal growth factor receptor monoclonal antibody C225 and protein kinase a antisense oligonucleotide hyb 165 (1999) (0)
Cytotoxic effect of the conjugate of anti egf receptor for monoclonal antibody to ricin a chain on human tumor cells (1987) (0)
Modulation of cytosine arabinoside tri phosphate and tri nucleotide pools in a human acute leukemia cell line hl 60 by thymidine and hydroxy urea (1981) (0)
Infusional 5-FU radiosensitization in human cancers: Status report (1979) (0)
TARGETED THERAPY WITH MONOCLONAL ANTIBODIES (mAbs) (1993) (0)
Personalized therapy in diverse cancers: Meta-analysis of 32,149 patients in phase II clinical trials. (2015) (0)
Cytotoxic and antitumor activity of canavanine (CANA) (1979) (0)
Role of AKT in chemotherapy-mediated cytotoxicity in MCF-7 breast cancer cells (2001) (0)
Growth of tumor colony forming units from human tumor xenografts: potential applications. Abstr. (1980) (0)
Monoclonal antibodies to the EGF receptor selectively inhibit the growth of human tumor cells (1985) (0)
Reciprocal Changes in 27 Kq and p 2 lC in Growth Inhibition Mediated by Blockade or Overstimulation of Epidermal Growth Factor Receptors 1 (2005) (0)
Cancer biology: Editorial overview (1991) (0)
Clinical Cancer Research: Editorial (1999) (0)
Expression of Epidermal Growth Factor Receptor in Human Cultured Cells and Tissues: Relationship to Cell Lineage and Stage of Differentiation1 (2006) (0)
Abstract 668: Induction of mammary carcinoma in tetracycline-inducible cMET(T1010I) transgenic mice (2016) (0)
Thymidine (TdR) as a potential chemotherapeutic agent: cytokinetic studies (1981) (0)
Kinetics of DNA synthesis, cell proliferation and cell death in human lymphocyte stimulation by phytohemagglutinin (PHA) (1976) (0)
Lymphocyte PHA and PPD stimulation as an in vitro model for recruitment: proliferation kinetics of the system (1976) (0)
PITFALLS IN THE LYMPHOCYTE PROLIFERATION ASSAY: VARIATIONS IN PROLIFERATION KINETICS AND COLD THYMIDINE POOLS (1977) (0)
Combination Therapy with Cisplatinum and EGF Receptor Blockade (1996) (0)
DAN Synthesis and Proliferation of Human Lymphocytes in Vitro (1978) (0)
Antiangiogenic and antitumor effect of VEGF antisense oligonucleotide in combination with anti-EGFR C225 monoclonal antibody in human colon cancer (1999) (0)
The roles of transferrin(TF), transferrin receptors (TFR) and FE in hemopoietic cell growth: Receptor-ligand interactions in the presence of an anti-receptor antibody(AB) (1985) (0)
ADENYLATE CYCLASE IN NORMAL AND LEUKEMIC HUMAN LYMPHOCYTES (1979) (0)
Operations, Oversight, and Funding of Cancer Clinical Trials (2010) (0)
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial (2019) (0)
AND EGF RECEPTOR BLOCKADE (1996) (0)
Control of Transcription in the Human Lymphocyte. (1973) (0)
Abstract PR13: Investigating the importance of low allele frequency mutations for cancer patient management (2015) (0)
Breast Cancer Therapy Using Monoclonal Antibodies Against Epidermal Growth Factor Receptor and HER-2 (1999) (0)
Bristol-Myers Squibb Announces Awards (2004) (0)
Growth stimulation of A431 cells b} Identification of high-affinity recep factor by an anti-receptor monocloi (hormone receptors/mitogenesis) (2016) (0)
ASCO: Recent Advances in Using a “Systems Approach” in Oncology (2011) (0)

This paper list is powered by the following services:

Other Resources About John Mendelsohn

en.wikipedia.org

What Schools Are Affiliated With John Mendelsohn ?

John Mendelsohn is affiliated with the following schools: